

2024 Annual General Meeting

PYC Therapeutics Limited (ASX:PYC) (**PYC** or the **Company**) advises that the Annual General Meeting of the Company (**AGM**) will be held on Wednesday, 13 November 2024 at 09:00 am AWST.

The AGM will be held at the Auditorium, The Harry Perkins Institute of Medical Research, QEII Medical Centre, 6 Verdun Street, Nedlands, Western Australia.

Please see attached a Notice of Annual General Meeting and a letter to shareholders advising further detail of the meeting and accessing meeting documents.

This announcement was approved for release by the Board of PYC Therapeutics Limited.

For further information, please contact:

Andrew Taylor
Company Secretary
info@pyctx.com

About PYC Therapeutics

PYC Therapeutics (ASX: PYC) is a clinical-stage biotechnology company creating a new generation of RNA therapies to change the lives of patients with genetic diseases. The Company utilises its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class. PYC's drug development programs target monogenic diseases – **the indications with the highest likelihood of success in clinical development**¹.

PYC is conducting multiple concurrent clinical trials in two blinding diseases of childhood and has a third program targeting Polycystic Kidney Disease which is anticipated to progress into human trials in early 2025.

For more information, visit pyctx.com, or follow us on LinkedIn and X.

CONTACTS:

INVESTORS and MEDIA
info@pyctx.com

¹ Advancing Human Genetics Research and Drug Discovery through Exome Sequencing of the UK Biobank <https://doi.org/10.1101/2020.11.02.20222232>



14 October 2024

Dear Shareholders,

ANNUAL GENERAL MEETING – NOTICE AND PROXY FORM

PYC Therapeutics Limited's (**PYC or the Company**) 2024 Annual General Meeting is scheduled to be held at the Auditorium, The Harry Perkins Institute of Medical Research, QEII Medical Centre, 6 Verdun Street, Nedlands, Western Australia on Wednesday, 13 November 2024 at 9.00am (AWST) (**Meeting**).

In accordance with the *Corporations Amendments (Meetings and Documents) Act 2022* (Cth)) which came into effect on 1 April 2022, the Company will not be sending physical copies of the Notice of Meeting, and accompanying Explanatory Memorandum (**Meeting Materials**), to shareholders unless they have made a valid election to receive documents in physical copy.

Instead, a copy of the Meeting Materials will be available electronically under the "Shareholder Communication" section of the Company's website at <https://pyctx.com/investors-news-announcements/>.

As you have not elected to receive notices by email, a copy of your personalised proxy form is enclosed for your convenience.

Accordingly, the Directors **strongly encourage all Shareholders to lodge their directed proxy votes prior to the Meeting and appoint the Chair as their proxy** in accordance with the instructions set out in the proxy form. All voting at the Meeting will be conducted by poll.

If Shareholders do not attend the Meeting in person, they will be able to participate by:

- (a) voting prior to the Meeting by lodging the enclosed proxy form attached to the Notice of Meeting by no later than 9.00am (AWST) on 11 November 2024, as per the instructions on the proxy form; and
- (b) lodging questions in advance of the Meeting by emailing the questions to the CEO at info@pyctx.com by no later than 11 November 2024.

If you have any difficulties obtaining a copy of the Meeting Materials, please contact the Company Secretary at info@pyctx.com.

PYC shareholders who wish to update their details to be able to receive communications and notices electronically can do so by visiting the Company's share registry website at <https://investor.automic.com.au> and registering an account.

Sincerely,

Andrew Taylor
Company Secretary



PYC Therapeutics Limited
ACN 098 391 961

Notice of Annual General Meeting

THIS IS AN IMPORTANT DOCUMENT AND REQUIRES YOUR ATTENTION

If you are in any doubt as to the contents of this document or how to deal with it, please consult your financial or other professional adviser.

The Annual General Meeting will be held:

- at the Auditorium, The Harry Perkins Institute of Medical Research, QEII Medical Centre, 6 Verdun Street, Nedlands, Western Australia
- on Wednesday, 13 November 2024 at 9.00am AWST

You can vote by:

- attending and voting at the meeting; or
- appointing someone as your proxy to attend and vote at the meeting on your behalf, by completing and returning the Proxy Form to the Company in the manner set out in the Proxy Form accompanying this Notice.

PYC Therapeutics Limited
ACN 098 391 961
(Company)

Notice of Annual General Meeting

Notice is given that the annual general meeting of PYC Therapeutics Limited will be held at the Auditorium in The Harry Perkins Institute of Medical Research, QEII Medical Centre, 6 Verdun Street, Nedlands, Western Australia on Wednesday, 13 November 2024 at 9.00am AWST.

An Explanatory Memorandum containing information on each of the following Resolutions accompanies this Notice. The Explanatory Memorandum and the Proxy Form forms part of this Notice. This Notice of Annual General meeting also includes at **Schedule 3** information with respect to your right to elect to receive documents electronically or physically as required by The *Corporations Amendment (Meetings and Documents) Act 2022* (Amendment Act).

Terms used in this Notice are defined in **Schedule 1**.

Agenda

1 Annual Report

To receive and consider the Annual Report of the Company for the financial year ended 30 June 2024 which includes the Financial Report, Directors' Report and Auditor's Report.

2 Resolutions

Resolution 1: Remuneration Report

To consider and, if thought fit, pass the following as an **ordinary resolution**:

'That the Remuneration Report for the year ended 30 June 2024 be adopted by the Company.'

Note: Votes on this Resolution are advisory only and do not bind the Directors or the Company. A voting exclusion applies to this Resolution (see below).

Resolution 2: Re-elect Mr Jason Haddock as a Director of the Company

To consider and, if thought fit, pass the following as an **ordinary resolution**:

'That Mr. Jason Haddock be re-elected as a Director.'

Resolution 3: Consolidation of Securities

To consider and, if thought fit, pass the following as an **ordinary resolution**:

'That for the purposes of section 254H of the Corporations Act, Listing Rule 7.20 and for all other purposes, approval is given for the consolidation of the Company's existing Securities on the basis that:

(a) Every 10 Shares be consolidated into 1 Share; and

(b) Every 10 Options be consolidated into 1 Option,

with fractional entitlements rounded down to the nearest whole number, on the terms and conditions set out in the Explanatory Memorandum.'

Voting Exclusion Statement

Resolution 1: In accordance with the Corporations Act, a vote on Resolution 1 must not be cast by, or on behalf of, a member of the Key Management Personnel whose remuneration details are included in the Remuneration Report, or a Closely Related Party of such member.

However, the Company need not disregard a vote on Resolution 1 if:

- (a) it is cast by a person as proxy for a person who is entitled to vote, in accordance with the directions on the Proxy Form; or
- (b) it is cast by the Chair pursuant to an express authorisation to exercise the proxy even if this Resolution 1 is connected directly or indirectly with the remuneration of the Key Management Personnel.

By order of the Board



Andrew Taylor
Company Secretary
PYC Therapeutics Limited

Date: 14 October 2024

PYC Therapeutics Limited
ACN 098 391 961
(Company)

Explanatory Memorandum

1. Introduction

This Explanatory Memorandum has been prepared for the information of Shareholders in connection with the business to be conducted at the Meeting. The Explanatory Memorandum forms part of the Notice which should be read in its entirety.

2. Action to be taken by Shareholders

Shareholders should read the Notice including this Explanatory Memorandum carefully before deciding how to vote on the Resolutions.

2.1 Voting entitlement

The Directors have determined pursuant to Regulation 7.11.37 of the Corporations *Regulations 2001* (Cth) that the persons eligible to vote at the Meeting are those who are registered Shareholders at 4.00pm AWST on Monday, 11 November 2024.

2.2 Voting in person

To vote in person, attend the Meeting on the date and at the place set out above. in the Notice.

If you attend the Meeting, please bring your personalised Proxy Form with you to assist with registration. If you do not bring your form with you, you will still be able to attend the Meeting but you will need to verify your identity.

2.3 Voting by proxy

A Proxy Form is located at the end of the Explanatory Memorandum.

To vote by proxy, please use one of the following methods:

Online	visiting https://investor.automic.com.au/#/loginsah or by scanning the QR code, found on the Proxy Form with your mobile device
By post	Automic Group, GPO Box 5193, Sydney NSW 2001
By hand	Automic, Level 5, 126 Phillip Street, Sydney NSW 2000

Your Proxy instruction must be received not later than 48 hours before the commencement of the Meeting. **Proxy Forms received later than this time will be invalid.**

2.4 Power of Attorney

If the Proxy Form is signed under a power of attorney on behalf of a Shareholder, then the attorney must make sure that either the original power of attorney or a certified copy is sent with the Proxy Form, unless the power of attorney has already been provided to the Registry.

2.5 **Corporate Representatives**

If a representative of a corporate shareholder or a corporate proxy will be attending the Meeting, the representative should bring to the Meeting adequate evidence of their appointment, unless this has previously been provided to the Registry.

2.6 **Chair's voting intentions**

The Chair intends to exercise all available proxies in favour of all Resolutions, unless the Shareholder has expressly indicated a different voting intention.

If the Chair is your proxy, either by appointment or by default, and you have not indicated your voting intention, you expressly authorise the Chair to exercise the proxy in respect of Resolution 1 even though these Resolutions are connected directly or indirectly with the remuneration of the Company's Key Management Personnel.

3. **Annual Report**

The Corporations Act requires the Company's Financial Report, Directors' Report and Auditors Report for the last financial year to be presented to the Annual General Meeting. The Financial Report, Directors' Report and Auditor's Report are contained in the 2024 Annual Report.

The Annual Report is available from the Company's website at www.pyctx.com

No resolution is required to be moved in respect of this item.

Shareholders will be given a reasonable opportunity at the Annual General Meeting to ask questions and make comments on the accounts and on the management of the Company.

The Auditor will be present at the Meeting. The Chair will also give Shareholders a reasonable opportunity to ask the Auditor or the Auditor's representative questions relevant to:

- (a) the conduct of the audit;
- (b) the preparation and content of the independent audit report;
- (c) the accounting policies adopted by the Company in relation to the preparation of the financial statements; and
- (d) the independence of the Auditor by the Company in relation to the conduct of the audit.

The Chair will also allow a reasonable opportunity for the Auditor or their representative to answer any written questions submitted to the Auditor under section 250PA of the Corporations Act.

4. **Resolution 1: Adoption of Remuneration Report**

4.1 **Background**

The Corporations Act requires a resolution that the adoption of the Company's Remuneration Report be put to a vote at its Annual General Meeting.

The Remuneration Report explains the Board's policies in relation to the nature and level of remuneration paid to the Key Management Personnel (including the Directors), sets out details of the remuneration and service agreements for each member of Key Management Personnel and sets out the details of any share-based compensation.

An opportunity will be given to Shareholders as a whole, to ask questions about, or make comments on, the Remuneration Report. The Remuneration Report is set out in the Annual Report which is available online at www.pyctx.com

Resolution 1 is advisory only and does not bind the Directors or the Company. If, Resolution 1 is not passed, the Directors will not be required to alter any of the arrangements in the Remuneration Report. However, the Board will take the outcome of the vote very seriously when considering the Company's future remuneration policy.

If the Company's Remuneration Report receives a 'no' vote of 25% or more (**Strike**) at two consecutive annual general meetings, Shareholders will have the opportunity to remove the whole Board, except the managing director (if any).

Where a resolution on the Remuneration Report receives a Strike at two consecutive annual general meetings, the Company will be required to put to Shareholders at the second annual general meeting a resolution on whether another meeting should be held (within 90 days) at which all Directors (other than the managing director, if any) who were in office at the date of approval of the applicable Directors' Report must stand for re-election.

The Company's Remuneration Report did not receive a Strike at the 2023 Annual General Meeting. If the Remuneration Report receives a Strike at this Meeting, Shareholders should be aware that if a second Strike is received at the 2025 Annual General Meeting, this may result in the re-election of the Board.

The Chair will allow a reasonable opportunity for Shareholders as a whole to ask about or make comments on the Remuneration Report.

4.2 **Recommendation**

The Directors unanimously recommend that Shareholders vote in favour of Resolution 1. The Chair of the meeting intends to vote all available proxies in favour of Resolution 1.

5. **Resolution 2: Re-Election of Mr Jason Haddock**

5.1 **Background**

Mr Jason Haddock is a Non-Executive Director of the Company. Mr Haddock was first appointed to the Board on 29 March 2021 and was last re-elected at the 2021 AGM held on 18 November 2021.

Mr Haddock retires as a Director by way of rotation pursuant to Rule 20.6 of the Constitution at the conclusion of the Meeting. Mr Haddock offers himself, and is eligible for, re-election at this Meeting.

If Resolution 2 is passed, Mr Haddock will be re-elected as Non-Executive Director of the Company. If Mr Haddock is not re-elected, Mr Haddock will retire as a Director. The Board may consider an alternative Director be appointed, with ratification at the Company's next AGM.

5.2 **Profile**

Jason Haddock has more than 20 years of financial and operational experience in the biopharmaceutical industry. He served as CFO at Array BioPharma, Inc., where he was instrumental in the execution of an oncology-focused research, development and commercialization strategy that culminated in the successful launch of two new drugs and the company ultimately being acquired by Pfizer.

Prior, he worked at Bristol-Myers Squibb in a variety of finance, strategic, commercial and business development capacities, including CFO and COO roles for business units in Asia Pacific, Europe and the United States. Mr. Haddock has also served as CFO for ArcherDX as the company was acquired by Invitae to create a global leader in comprehensive cancer genetics and precision oncology. He holds a BS in accounting from Illinois State University and an EMBA from Washington University in St. Louis.

Mr Haddock has held no other Australian listed company directorships in the last three years.

5.3 **Recommendation**

The Directors (other than Mr Haddock) recommend that Shareholders vote in favour of the re-election of Mr Haddock as set out in this Resolution 2. Mr Haddock makes no recommendation in respect of Resolution 2. The Chair of the meeting intends to vote all available proxies in favour of Resolution 2.

If re-elected, the Board considers that Mr Haddock will be an independent Director.

6. **Resolution 3: Consolidation of Securities**

6.1 **Background**

Resolution 3 seeks Shareholder approval to undertake a consolidation of the number of shares on issue on the basis that every 10 Shares held be consolidated into one (1) (**Consolidation**). Similarly, the number of Options on issue will be consolidated on the basis that every 10 Options held will be consolidated into one (1) Option. The exercise price of the Options will be amended in inverse proportion to the consolidation ratio.

6.2 **Regulatory Requirements**

(a) ***Purpose of proposed resolution***

The Directors have proposed the Consolidation for the following reasons:

- (i) The Company currently has 4,666,083,409 shares on issue which represents a relatively large number when compared to its listed peer group;
- (ii) The Directors consider that the consolidation will assist in reducing the volatility of the Company's share price and enable a more consistent valuation of the Company; and
- (iii) The Consolidation is also expected to assist in positioning the Company for long term growth by making an investment in the Company's Securities more attractive to institutional and other investors.

(b) ***Legal Requirements***

Section 254H of the Corporations Act provides that a Company may, by resolution passed at a general meeting, convert all or any of its shares into a larger or smaller number.

Listing Rule 7.20 provides that where an entity proposes to reorganise its capital, it must tell shareholders:

- (i) The effect of the proposal on the number of securities and the amount paid (if any) on the securities;
- (ii) The proposed treatment of any fractional entitlements arising from the reorganisation; and
- (iii) The proposed treatment of any convertible securities on issue.

Listing Rule 7.20 provides that where an entity proposes to reorganise its capital, it must tell shareholders

Listing Rule 7.22.1 provides that where a listed entity with options undertakes a consolidation of its capital, the number of its options must be consolidated in the same ratio as the ordinary capital and the exercise price must be amended in inverse proportion to that ratio.

(c) ***Effect of Consolidation***

The result of the Consolidation is that each security holding will be reduced by 10 times its current level.

As the Consolidation applies equally to all Shareholders, individual Shareholders will be reduced in the same ratio as the total number of Shares (subject to rounding). Accordingly, assuming no other market movements or impacts occur, the Consolidation will have no effect on the percentage interest in the Company of each Shareholder.

The Consolidation will not result in any change to the substantive rights and obligations of existing Shareholders.

The change in capital structure of the Company following the Consolidation, subject to adjustment for rounding is as follows:

Shares	Number ¹
Shares currently on issue	4,666,083,409
Shares on issue after Consolidation ²	466,608,340

1. Assumes no Options exercised prior to Consolidation

2. Subject to rounding of individual shareholdings post Consolidation

The Change in Options on issue following the Consolidation is as follows:

Expiry Date	Pre Consolidated Number	Post Consolidated Number on a 1:10 basis	Pre Consolidated Exercise Price	Post Consolidated Exercise Price
28/02/2031	2,000,000	200,000	\$0.17	\$1.70
23/03/2031	2,500,000	250,000	\$0.17	\$1.70
29/03/2031	2,500,000	250,000	\$0.17	\$1.70
23/11/2024	500,000	50,000	\$0.17	\$1.70
20/04/2026	2,400,000	240,000	\$0.17	\$1.70
30/09/2026	5,000,000	500,000	\$0.17	\$1.70
30/09/2026	1,000,000	100,000	\$0.17	\$1.70
30/09/2026	1,300,000	130,000	\$0.17	\$1.70
30/09/2026	1,100,000	110,000	\$0.17	\$1.70
30/09/2026	1,300,000	130,000	\$0.17	\$1.70
30/09/2026	1,200,000	120,000	\$0.17	\$1.70
30/09/2026	1,000,000	100,000	\$0.17	\$1.70
30/09/2026	1,000,000	100,000	\$0.17	\$1.70
30/09/2026	1,800,000	180,000	\$0.17	\$1.70
10/02/2027	1,500,000	150,000	\$0.17	\$1.70
28/09/2027	1,000,000	100,000	\$0.09	\$0.90
01/10/2027	2,500,000	250,000	\$0.09	\$0.90
22/05/2028	21,000,000	2,100,000	\$0.17	\$1.70
01/07/2028	2,000,000	200,000	\$0.17	\$1.70
Total	52,600,000	5,260,000		

Note: assumes no options are exercised or forfeited prior to Consolidation.

(d) ***Fractional entitlements***

Where the Consolidation results in an entitlement to a fraction of a Share or Option, that fraction will be rounded down to the nearest whole number of Shares or Options.

(e) ***Holding statements***

Taking effect from the date of the Consolidation, all existing holding statements will cease to have any effect, except as evidence of entitlement to a certain number of Securities on a post-consolidation basis. New holding statements will be issued to security holders, who are encouraged to check their holdings after the Consolidation.

(f) ***Taxation***

The Consolidation should not result in a capital gains tax event for Australian tax residents. The cost base of the Shares held after the Consolidation will be the sum of the cost bases of the original Shares pre-consolidation. The acquisition date of Shares held after the Consolidation will be the same as the date on which the original Shares were acquired.

This Explanatory Memorandum does not however consider the tax implications in respect of Shares or other Securities held on revenue account, as trading stock or by non-resident Shareholders. Shareholders should consider their own circumstances and seek their own professional advice in relation to their tax position. Neither the Company nor any of its officers or employees assumes any liability or responsibility for advising Shareholders or other security holders about the tax consequences of the proposed Consolidation.

6.3 Timetable

If Resolution 3 is passed, the Consolidation will take effect in accordance with the following timetable (as set out in Appendix 7A (paragraph 7) of the Listing Rules):

Date	Event
14 October 2024	Announcement of Consolidation and issue of Appendix 3A.3 notice
13 November 2024	Meeting held with Resolution to approve Consolidation. Company notifies ASX that Consolidation is approved
13 November 2024	Effective date of consolidation
14 November 2024	Last day for trading in pre-consolidation Securities
15 November 2024	Unless otherwise determined by ASX, trading in post-Consolidated Securities commences on a deferred settlement basis
18 November 2024	Record Date for Consolidation. Last day for entity to register transfers on a pre-consolidation basis
19 November 2024	First day for entity to update Register and send holding statements to security holders reflecting the change in the number of Securities they hold
25 November 2024	Last day for entity to update Register and send holding statements to security holders reflecting the change in the number of Securities they hold and to notify ASX that this has occurred.

6.4 Consequences of the Resolution

If Resolution 3 is passed, the Company will be able to proceed with the Consolidation and the number of Securities in the Company will be consolidated as set out above, on the timetable set out above in section 6.3.

If Resolution 3 is not passed, the Company will not proceed with the Consolidation.

6.5 Recommendation

The Directors unanimously recommend that all Shareholders vote in favour of this Resolution 3. The Chair of the meeting intends to vote all available proxies in favour of Resolution 3.

Schedule 1 – Definitions

In this Notice:

Term	Meaning
AWST	Australian Western Standard Time.
Annual Report	The Directors' Report, the Financial Report and the Auditor's Report in respect to the financial year ended 30 June 2024.
ASX	The ASX Limited (ABN 98 008 624 691) and, where the context permits, the Australian Securities Exchange operated by ASX Limited.
Auditor	PricewaterhouseCoopers.
Auditor's Report	The auditor's report on the Financial Report.
Board	The board of Directors of the Company.
Chair	The person appointed to chair the Meeting of the Company convened in the Notice.
Closely Related Party	has the meaning given in section 9 of the Corporations Act.
Company or PYC	PYC Therapeutics Limited ACN 098 391 961.
Constitution	The constitution of the Company as at the date of the Meeting.
Consolidation	Every 10 Shares to be consolidated into 1 Share and every 10 options to be converted into 1 option.
Corporations Act	The <i>Corporations Act 2001</i> (Cth).
Director	A director of the Company.
Directors' Report	The annual directors' report prepared under Chapter 2M of the Corporations Act for the Company and its controlled entities.
Equity Security	has the same meaning as in the Listing Rules.
Explanatory Memorandum	The Explanatory Memorandum which forms part of this Notice.
Financial Report	The annual financial report prepared under Chapter 2M of the Corporations Act of the Company and its controlled entities.

Key Management Personnel or KMP	has the same meaning as in the accounting standards issued by the Australian Accounting Standards Board and means those persons having authority and responsibility for planning, directing and controlling the activities of the Company, or if the Company is part of a consolidated entity, of the consolidated entity, directly or indirectly, including any Director (whether executive or otherwise) of the Company, or if the Company is part of a consolidated entity, of an entity within the consolidated group.
Listing Rules	The listing rules of ASX.
Meeting	The Annual General Meeting convened by the Notice.
Notice	This notice of Meeting.
Proxy Form	The proxy form attached to the Notice.
Remuneration Report	The remuneration report of the Company contained in the Directors' Report.
Registry	Atomic Group, the Company's Registry.
Resolution	A resolution referred to in the Notice.
Schedule	A schedule to the Notice.
Section	A section of the Explanatory Memorandum.
Securities	Any Equity Securities of the Company (including Shares, options and/or performance rights).
Share	A fully paid ordinary share in the capital of the Company.
Shareholder	The holder of a Share.
\$	A reference to "\$" is to Australian currency.

Schedule 3 – Your right to elect to receive documents electronically or physically

The *Corporations Amendment (Meetings and Documents) Act 2022* (**Amendment Act**) includes a new requirement for public companies and listed companies to give shareholders notice of their right to elect to be sent documents electronically or physically by the company in section 110K of the Corporations Act.

Recent legislative changes to the Corporations Act 2001 (Cth) mean there are new options for how **PYC Therapeutics Limited** shareholders receive communications. **PYC Therapeutics Limited** will no longer send physical meeting documents unless a shareholder requests a copy to be mailed.

Providing your email address to receive shareholder communications electronically

PYC Therapeutics Limited encourages all shareholders to provide an email address so we can provide investor communications electronically when they become available online, which includes items such as meeting documents and annual reports.

By providing your email address, you will:

- Support the company by reducing the cost of mailing/postage
- Receive your investor communications faster and in a more secure way
- Help the environment through the need for less paper

How do I update my communications preferences?

Shareholders can still elect to receive some or all of their communications in physical or electronic form or elect not to receive certain documents such as annual reports. To review your communications preferences, or sign up to receive your shareholder communications via email, please update your communication preferences at

<https://investor.automic.com.au/>

If you are a shareholder and would like a physical copy of a communication, need further information about the options available to you or have questions about your holding, visit

<https://investor.automic.com.au/> or contact our share registry:

Telephone (within Australia): 1300 288 664

Telephone (outside Australia): +61 2 9698 5414

Email: hello@automicgroup.com.au

Website: <https://investor.automic.com.au/>

Your proxy voting instruction must be received by **09.00am (AWST) on Monday, 11 November 2024**, being **not later than 48 hours** before the commencement of the Meeting. Any Proxy Voting instructions received after that time will not be valid for the scheduled Meeting.

SUBMIT YOUR PROXY

Complete the form overleaf in accordance with the instructions set out below.

YOUR NAME AND ADDRESS

The name and address shown above is as it appears on the Company's share register. If this information is incorrect, and you have an Issuer Sponsored holding, you can update your address through the investor portal: <https://investor.automic.com.au/#/home> Shareholders sponsored by a broker should advise their broker of any changes.

STEP 1 – APPOINT A PROXY

If you wish to appoint someone other than the Chair of the Meeting as your proxy, please write the name of that Individual or body corporate. A proxy need not be a Shareholder of the Company. Otherwise if you leave this box blank, the Chair of the Meeting will be appointed as your proxy by default.

DEFAULT TO THE CHAIR OF THE MEETING

Any directed proxies that are not voted on a poll at the Meeting will default to the Chair of the Meeting, who is required to vote these proxies as directed. Any undirected proxies that default to the Chair of the Meeting will be voted according to the instructions set out in this Proxy Voting Form, including where the Resolutions are connected directly or indirectly with the remuneration of Key Management Personnel.

STEP 2 - VOTES ON ITEMS OF BUSINESS

You may direct your proxy how to vote by marking one of the boxes opposite each item of business. All your shares will be voted in accordance with such a direction unless you indicate only a portion of voting rights are to be voted on any item by inserting the percentage or number of shares you wish to vote in the appropriate box or boxes. If you do not mark any of the boxes on the items of business, your proxy may vote as he or she chooses. If you mark more than one box on an item your vote on that item will be invalid.

APPOINTMENT OF SECOND PROXY

You may appoint up to two proxies. If you appoint two proxies, you should complete two separate Proxy Voting Forms and specify the percentage or number each proxy may exercise. If you do not specify a percentage or number, each proxy may exercise half the votes. You must return both Proxy Voting Forms together. If you require an additional Proxy Voting Form, contact Automic Registry Services.

SIGNING INSTRUCTIONS

Individual: Where the holding is in one name, the Shareholder must sign.

Joint holding: Where the holding is in more than one name, all Shareholders should sign.

Power of attorney: If you have not already lodged the power of attorney with the registry, please attach a certified photocopy of the power of attorney to this Proxy Voting Form when you return it.

Companies: To be signed in accordance with your Constitution. Please sign in the appropriate box which indicates the office held by you.

Email Address: Please provide your email address in the space provided.

By providing your email address, you elect to receive all communications despatched by the Company electronically (where legally permissible) such as a Notice of Meeting, Proxy Voting Form and Annual Report via email.

CORPORATE REPRESENTATIVES

If a representative of the corporation is to attend the Meeting the appropriate 'Appointment of Corporate Representative' should be produced prior to admission. A form may be obtained from the Company's share registry online at <https://automic.com.au>.

Lodging your Proxy Voting Form:

Online

Use your computer or smartphone to appoint a proxy at <https://investor.automic.com.au/#/loginsah> or scan the QR code below using your smartphone

Login & Click on 'Meetings'. Use the Holder Number as shown at the top of this Proxy Voting Form.



BY MAIL:

Automic
GPO Box 5193
Sydney NSW 2001

IN PERSON:

Automic
Level 5, 126 Phillip Street
Sydney NSW 2000

BY EMAIL:

meetings@automicgroup.com.au

BY FACSIMILE:

+61 2 8583 3040

All enquiries to Automic:

WEBSITE:

<https://automicgroup.com.au/>

PHONE:

1300 288 664 (Within Australia)
+61 2 9698 5414 (Overseas)

